Co-Authors
This is a "connection" page, showing publications co-authored by ROBERT A WOLFF and MARC E DELCLOS.
Connection Strength
0.477
-
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol. 2006 Mar 01; 24(7):1145-51.
Score: 0.071
-
Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):323-332.
Score: 0.037
-
Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS One. 2016; 11(6):e0156910.
Score: 0.036
-
Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):755-65.
Score: 0.035
-
Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol. 2015 Jul; 54(7):971-8.
Score: 0.033
-
Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer. 2013 Nov 01; 119(21):3769-75.
Score: 0.030
-
Reirradiation to the abdomen for gastrointestinal malignancies. Radiat Oncol. 2009 Nov 18; 4:55.
Score: 0.023
-
Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):1175-80.
Score: 0.020
-
Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. Int J Radiat Oncol Biol Phys. 2008 Mar 01; 70(3):735-43.
Score: 0.020
-
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007 Jul 01; 110(1):47-55.
Score: 0.020
-
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer. 2006 Dec 01; 107(11):2589-96.
Score: 0.019
-
Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):762-71.
Score: 0.019
-
Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol. 2006 Oct 24; 1:41.
Score: 0.019
-
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1378-83.
Score: 0.019
-
Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol. 2006 Jun; 29(3):219-24.
Score: 0.018
-
Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. Am J Clin Oncol. 2005 Jun; 28(3):227-33.
Score: 0.017
-
Chemoradiation for adenocarcinoma of the anus. Int J Radiat Oncol Biol Phys. 2003 Mar 01; 55(3):669-78.
Score: 0.014
-
Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer. 2003 Jan 15; 97(2):517-24.
Score: 0.014
-
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys. 2002 Apr 01; 52(5):1293-302.
Score: 0.014